VGLL3 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-9184R-Cy5.5 |
| Product Name | VGLL3 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
IF(IHC-P)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human VGLL3 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 389136 |
| Synonyms | Colon carcinoma related protein; Vestigial like 3 Drosophila; VGL 3; VGL-3; VGL3; VGLL3_HUMAN. |
| Background | The transcriptional enhancer factor-1 (TEF-1) family of transcription factors regulate tissue-specific gene expression in muscle and placenta. The mechanism whereby TEF-1 confers tissue specificity depends largely on the interaction of TEF-1 with tissue-specific cofactors. Transcription cofactor Vgl-3 (vestigial-like protein 3), also known as colon carcinoma related protein, is a 326 amino acid nuclear protein that may act as a specific coactivator for the mammalian transcription elongation factors. Both Vgl-1 and Vgl-3 are enriched in placenta, whereas Vgl-2 is expressed in differentiating somites and branchial arches during embryogenesis and is skeletal-muscle specific in adult tissues. There are two isoforms of Vgl-3 that are produced as a result of alternative splicing events. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |